文献速递慢性肾脏病血液净化与透析肾血管病与高血压

卡格列净对CREDENCE试验中铁代谢的影响

Canagliflozin and iron metabolism in the CREDENCE trial.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

该研究为CREDENCE试验的事后分析,评估卡格列净对2型糖尿病合并慢性肾脏病患者铁代谢的影响,并探讨铁缺乏是否改变其对血红蛋白及心肾结局的作用。结果显示卡格列净增加总铁结合力、降低铁蛋白,提示铁利用增加,且无论有无铁缺乏均改善血红蛋白及临床结局。

要点

  • 2型糖尿病合并CKD患者中铁缺乏普遍,基线铁蛋白等可评估铁利用状态。
  • 卡格列净提高总铁结合力并降低铁蛋白,提示铁利用增加而非铁缺乏加重。
  • 无论有无铁缺乏,卡格列净均改善血红蛋白及心肾结局,无需因铁缺乏调整使用。

核心结论

  • 卡格列净增加总铁结合力并降低铁蛋白,提示铁利用增加,且无论有无铁缺乏均改善血红蛋白及临床结局。

研究设计与样本

  • CREDENCE试验事后分析,纳入随机分组且有基线铁指标检测的2416例2型糖尿病合并CKD患者。

主要发现

  • 基线铁缺乏(转铁蛋白饱和度<20%)者924例,占38.2%。
  • 卡格列净对血清铁或转铁蛋白饱和度无明显影响。

临床怎么用

  • 在2型糖尿病合并CKD患者中,卡格列净可改善铁利用指标和血红蛋白,无需因铁缺乏而停用。
  • 铁缺乏状态不影响卡格列净对心肾结局的获益,支持其在此类患者中的使用。

局限性

  • 为事后分析,仅54.9%的随机参与者有基线铁指标检测。
  • 铁指标仅在基线和12个月测量,缺乏更长期动态数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies in patients with heart failure have indicated that sodium-glucose cotransporter 2 (SGLT2) inhibitors increase iron use and enhance erythropoiesis. In this post hoc analysis of the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, we evaluated the effects of canagliflozin on iron metabolism in patients with chronic kidney disease (CKD) and whether the effects of canagliflozin on hemoglobin and cardiorenal outcomes were modified by iron deficiency. METHODS: We measured serum iron, total iron binding capacity (TIBC), transferrin saturation (TSAT) and ferritin at baseline and 12 months. The effects of canagliflozin, relative to placebo, on iron markers were assessed with analysis of covariance. Interactions between baseline iron deficiency, defined as TSAT <20%, and the effects of canagliflozin on hemoglobin and cardiorenal outcomes were evaluated with mixed effect models and Cox regression models, respectively. RESULTS: Of 4401 participants randomized in CREDENCE, 2416 (54.9%) had iron markers measured at baseline, of whom 924 (38.2%) were iron deficient. Canagliflozin, compared with placebo, increased TIBC by 2.1% [95% confidence interval (CI) 0.4, 3.8; P = .014] and decreased ferritin by 11.5% (95% CI 7.1, 15.7; P < .001) with no clear effect on serum iron or TSAT. Canagliflozin increased hemoglobin over the trial duration by 7.3 g/L (95% CI 6.2, 8.5; P < .001) and 6.7 g/L (95% CI 5.2, 8.2; P < .001) in patients with and without iron deficiency, respectively (P for interaction = .38). The relative effect of canagliflozin on the primary outcome of doubling of serum creatinine, kidney failure or death due to cardiovascular disease or kidney failure (hazard ratio 0.70, 95% CI 0.56, 0.87) was consistent regardless of iron deficiency (P for interaction = .83), as were effects on other cardiovascular and mortality outcomes (all P for interactions ≥0.10). CONCLUSION: Iron deficiency is highly prevalent in patients with type 2 diabetes and CKD. Canagliflozin increased TIBC and decreased ferritin in patients with type 2 diabetes and CKD, suggesting increased iron utilization, and improved hemoglobin levels and clinical outcomes regardless of iron deficiency.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Koshino A, Heerspink HJL, Jongs N, et al. Canagliflozin and iron metabolism in the CREDENCE trial. Nephrol Dial Transplant. 2025. PMID: 39304530. doi:10.1093/ndt/gfae198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。